TSE:IMVIMV Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Imv Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$4.00 -0.18 (-4.31 %) (As of 06/4/2020 06:57 AM ET) Add Compare Share Today's RangeC$3.92Now: C$4.00▼C$4.1050-Day RangeC$2.15MA: C$3.47▼C$5.1052-Week RangeC$1.98Now: C$4.00▼C$6.69Volume81,929 shsAverage Volume130,388 shsMarket CapitalizationC$241.82 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. The company has collaboration and license agreement with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingIMV has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$5.67, IMV has a potential upside of 41.7% from its current price of C$4.00.Amount of Analyst CoverageIMV has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesIMV has received 83 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIMV has received 57 “underperform” votes. (Add your “underperform” vote.)Community SentimentIMV has received 59.29% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote “Outperform” if you believe IMV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIMV does not currently pay a dividend.Dividend GrowthIMV does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IMV insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IMV are expected to grow in the coming year, from C($0.55) to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IMV is -7.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IMV is -7.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIMV has a P/B Ratio of 31.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.38 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:IMV Previous Symbol CUSIPN/A CIKN/A Webwww.imvaccine.com Phone+1-902-4921819Debt Debt-to-Equity Ratio151.50 Current Ratio3.06 Quick Ratio2.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$59,000.00 Price / Sales4,098.58 Cash FlowC$0.22 per share Price / Cash Flow18.48 Book ValueC$0.13 per share Price / Book31.50Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees51 Outstanding Shares60,454,000Market CapC$241.82 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable TSX:IMV Rates by TradingView Receive IMV News and Ratings via Email Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter. IMV (TSE:IMV) Frequently Asked Questions How has IMV's stock been impacted by COVID-19 (Coronavirus)? IMV's stock was trading at C$3.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IMV stock has increased by 18.0% and is now trading at C$4.00. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of IMV? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IMV. When is IMV's next earnings date? IMV is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for IMV. How were IMV's earnings last quarter? Imv Inc (TSE:IMV) posted its quarterly earnings results on Monday, March, 30th. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.04. The firm earned $0.14 million during the quarter, compared to analyst estimates of $0.04 million. View IMV's earnings history. What price target have analysts set for IMV? 4 brokers have issued 12 month price targets for IMV's shares. Their forecasts range from C$3.00 to C$9.00. On average, they anticipate IMV's stock price to reach C$5.67 in the next year. This suggests a possible upside of 41.7% from the stock's current price. View analysts' price targets for IMV. Has IMV been receiving favorable news coverage? Media headlines about IMV stock have trended negative recently, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. IMV earned a news impact score of -2.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutIMV. Who are some of IMV's key competitors? Some companies that are related to IMV include Trillium Therapeutics (TRIL), BELLUS Health (BLU), Aptose Biosciences (APS), PureTech Health (PRTC), Bellus Health (BLU), Oxford BioMedica (OXB), CEL-SCI (CVM), Cel-Sci (CVM), Paradigm Biopharmaceuticals (PAR), SIGA Technologies (SIGA), Biotest (BIO), Neptune Wellness Solutions (NEPT), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX) and Starpharma (SPL). View all competitors. What other stocks do shareholders of IMV own? Based on aggregate information from My MarketBeat watchlists, some companies that other IMV investors own include Aurora Cannabis (ACB), International Road Dynamics (IRD), Village Farms International (VFF), Bombardier, Inc. Class B (BBD.B), Cronos Group (MJN), Aphria (APHA), Medical Facilities (DR), ReNeuron Group (RENE), Trevali Mining (TV) and Enbridge (ENB). Who are IMV's key executives? IMV's management team includes the following people: Mr. Frederic Ors, Pres, CEO & Director (Age 45)Mr. Pierre Labbé C.A., C.P.A., CPA, CA, ICD, Chief Financial Officer (Age 54)Dr. Gabriela Nicola Rosu M.D., Chief Medical OfficerMr. Joseph Sullivan, Sr. VP of Bus. Devel.Mr. Marc Jasmin CPA, CMA, Sr. Director of Investor Relations & Communications What is IMV's stock symbol? IMV trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV." How do I buy shares of IMV? Shares of IMV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is IMV's stock price today? One share of IMV stock can currently be purchased for approximately C$4.00. How big of a company is IMV? IMV has a market capitalization of C$241.82 million and generates C$59,000.00 in revenue each year. IMV employs 51 workers across the globe. What is IMV's official website? The official website for IMV is www.imvaccine.com. How can I contact IMV? IMV's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819. This page was last updated on 6/4/2020 by MarketBeat.com Staff
